By Jason Derry --
Alfacell Corp. and GENESIS
Pharma S.A. have announced an exclusive
licensing deal involving Alfacell's lead compound, ONCONASE®. The compound is in Phase IIIb clinical trials
for the treatment of unresectable malignant mesothelioma. Under the agreement, GENESIS will receive the
exclusive right to market and distribute ONCONASE® in Southeast Europe. Alfacell is a biopharmaceutical company whose
proprietary technology is ribonuclease therapeutics. GENESIS Pharma is a pharmaceutical company
focused on in-licensing, marketing, and distributing biotechnology products,
particularly in Southeast Europe.
Jason Derry, Ph.D., who graduated with honors from DePaul University
College of Law, is a molecular biologist and founding author of Patent Docs.
Comments